Home LiteratureArticle Details
PMID: 17199293 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

(alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.

Journal of the American Chemical Society ·Vol. 129 ·No. 1 ·2007-01-10 ·Pages 139-54

Sadowsky JD, Fairlie WD, Hadley EB, Lee HS, Umezawa N, Nikolovska-Coleska Z, Wang S, Huang DC, Tomita Y, Gellman SH

Abstract

The development of molecules that bind to specific protein surface sites and inhibit protein-protein interactions is a fundamental challenge in molecular recognition. New strategies for approaching this challenge could have important long-term ramifications in biology and medicine. We are exploring the concept that unnatural oligomers with well-defined conformations ("foldamers") can mimic protein secondary structural elements and thereby block specific protein-protein interactions. Here, we describe the identification and analysis of helical peptide-based foldamers that bind to a specific cleft on the anti-apoptotic protein Bcl-xL by mimicking an alpha-helical BH3 domain. Initial studies, employing a fluorescence polarization (FP) competition assay, revealed that among several alpha/beta- and beta-peptide foldamer backbones only alpha/beta-peptides intended to adopt 14/15-helical secondary structure display significant binding to Bcl-xL. The most tightly binding Bcl-xL ligands are chimeric oligomers in which an N-terminal alpha/beta-peptide segment is fused to a C-terminal alpha-peptide segment ((alpha/beta + alpha)-peptides)). Sequence-affinity relationships were probed via standard and nonstandard techniques (alanine scanning and hydrophile scanning, respectively), and the results allowed us to construct a computational model of the ligand/Bcl-xL complex. Analytical ultracentrifugation with a high-affinity (alpha/beta + alpha)-peptide established 1:1 ligand:Bcl-xL stoichiometry under FP assay conditions. Binding selectivity studies with the most potent (alpha/beta + alpha)-peptide, conducted via surface plasmon resonance measurements, revealed that this ligand binds tightly to Bcl-w as well as to Bcl-xL, while binding to Bcl-2 is somewhat weaker. No binding could be detected with Mcl-1. We show that our most potent (alpha/beta + alpha)-peptide can induce cytochrome C release from mitochondria, an early step in apoptosis, in cell lysates, and that this activity is dependent upon inhibition of protein-protein interactions involving Bcl-xL.

MeSH Terms
Alanine/chemistry Amino Acid Sequence Apoptosis/drug effects Cytochromes c/metabolism Drug Design Humans Ligands Mitochondria/drug effects Molecular Sequence Data Peptides/chemistry,pharmacology Protein Structure, Secondary Protein Structure, Tertiary Proto-Oncogene Proteins c-bcl-2/metabolism Recombinant Fusion Proteins/chemistry,pharmacology Structure-Activity Relationship bcl-X Protein/antagonists & inhibitors
Chemicals
Ligands Peptides Proto-Oncogene Proteins c-bcl-2 Recombinant Fusion Proteins bcl-X Protein Cytochromes c Alanine
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Sadowsky Jack D
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
Fairlie W Douglas
Hadley Erik B
Lee Hee-Seung
Umezawa Naoki
Nikolovska-Coleska Zaneta
Wang Shaomeng
Huang David C S
Tomita York
Gellman Samuel H
Article Info
Journal
Journal of the American Chemical Society
Abbr.
J Am Chem Soc
ISSN
0002-7863
Published
2007-01-10
Pages
139-54
Language
English
Region
United States
NLM ID
7503056
Subset
IM
Grants
NCI NIH HHS · CA43540 · United States
NCI NIH HHS · CA80188 · United States
NIGMS NIH HHS · GM56414 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com